GERN
What one share of Geron holds
Pharmaceutical Preparations
We commercially launched RYTELO in the U.S. in June 2024 following its approval by the U.S. Food and
Geron’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.10 |
|---|---|
| Cash and investments | $0.10 |
| Debt | $0.19 |
| Book value | $0.34 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $0.04 | −$0.19 | $0.00 | −$0.12 | — | $0.77 |
| 2017 | $0.01 | −$0.18 | — | −$0.13 | — | $0.65 |
| 2018 | $0.01 | −$0.15 | $0.00 | −$0.12 | — | $0.95 |
| 2019 | $0.00 | −$0.36 | $0.00 | −$0.23 | — | $0.68 |
| 2020 | $0.00 | −$0.28 | $0.00 | −$0.25 | — | $0.68 |
| 2021 | $0.00 | −$0.35 | $0.00 | −$0.29 | — | $0.39 |
| 2022 | $0.00 | −$0.37 | $0.00 | −$0.34 | — | $0.20 |
| 2023 | $0.00 | −$0.32 | $0.00 | −$0.30 | — | $0.46 |
| 2024 | — | −$0.27 | $0.00 | −$0.34 | — | $0.46 |
| 2025 | — | −$0.13 | — | −$0.17 | — | $0.35 |